Implexion

EnteroBiotix

This biopharmaceutical company develops orally administered microbial therapeutics for patients with gastrointestinal diseases, including irritable bowel syndrome and blood cancers.

AgomAb Therapeutics

This biopharmaceutical company develops therapies to treat fibrotic and inflammatory diseases for patients with conditions such as Crohn's disease and pulmonary fibrosis.

Calluna Pharma

This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.

Enterbiotix

This company develops orally administered microbiome therapeutics to treat patients with gastrointestinal conditions including irritable bowel syndrome and liver cirrhosis.

GenKyoTex

This biopharmaceutical company develops selective NOX inhibitors to treat patients with chronic inflammatory and fibrotic diseases such as primary biliary cholangitis.

Curzion Pharmaceuticals

This biopharmaceutical company develops oral small molecule therapies to treat patients with rare fibrotic conditions like diffuse cutaneous systemic sclerosis.

Apexian Pharmaceuticals

This company develops oral small molecule drugs targeting specific proteins to treat patients with cancer and inflammatory bowel diseases.

Eternygen

This biopharmaceutical company develops small molecule inhibitors targeting metabolic diseases, such as fatty liver and diabetes, for patients needing novel medical treatments.